EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.
days to go:
Expired
investment:
£376,230
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.
days to go:
Expired
investment:
£891,790
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
WELD is a fitness company on a mission to make on-demand health, fitness and wellbeing available to all ages & abilities. The company allows users and instructors to set the time and place for the training session, rent out their home or commercial spaces for activities, or interact 1-2-1 online. This approach, the company believes, helps personal trainers, hit by the Covid-19 lockdown, find clients. WELD also allows trainers to set their prices and keep 90% of their fees, and lets customers enjoy a 2% commission on referrals for every future session taken in perpetuity. WELD aims to tap into the $94 billion global fitness and wellness market that grew 8.7% from 2018/19. The company's primary target audience is Generation Z that, the company believes, embraced wellness. WELD will use the investment to improve its platform, boost marketing and plug the fitness & wellness gap.
days to go:
Expired
investment:
£199,227
Personalised Co. is a nutrition company on a mission to help as many people as possible reach their health and wellbeing goals by making supplements accessible and affordable. The company asserts that it provides personalised nutritional products to its consumers. Customers are required to take a quiz on the company's portal, based on which, the company's custom-built algorithm creates nutritionist-approved solutions tailored to the specific needs and goals of each customer. Personalised Co. has delivered 270,000 daily vitamin sachets till date. The company has also raised £192,000 from private investors and its first crowdfunding campaign in 2019. It achieved its milestone month in April 2020 earning £48,000 in revenue and delivering over 1,700 personalised vitamins and protein orders. The company will use the investment to level-up its operations, expand its product line and develop its companion-application.
days to go:
Expired
investment:
£401,417
Spotlight Consultations aims to diagnose diseases based on evidence-based questionnaires. The company's Algorithmic Questionnaire (AQ) strives to be a simple 3-5 minute questionnaire, dynamically responsive with each question linked to an actionable care pathway. The company estimates that 10% of global health expenditure per annum is spent on diabetes, which is predicted to rise to $825 billion by 2030. Indirect costs from premature death, disability, and diabetes-related health complications add an additional 35% more to this number. Spotlight intends for its AQ to help reduce expenditure and healthcare burden while improving the quality of care and health outcomes. The company will use the investment to support early revenue generation, team expansion and stimulate Research and Development (R&D) tools to cover more diseases like CVD, IBD, chronic pain, and cancers.
days to go:
Expired
investment:
£69,682
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.
days to go:
Expired
investment:
£142,026
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
Hussle is one of the UK's top fitness marketplace, providing many flexible fitness opportunities according to your requirement. The company has provided c.2.5M gym visits, raised £12M+ to date, and serviced more than 500k customers. The platform has c.40% of UK gyms and c.3,000 fitness venues. Besides a huge customer base, 10,000 new members are added to the facility each month. It has received a rating of 4.7 stars out of 5 on TrustPilot across 1,500 reviews. So far, Hussle has raised £12M+ from Albion, MMC, Concentric, TechnoGym, and Channel 4. With the proceeds, the company aims at creating a globally trusted fitness brand by enhancing the brand's awareness and by broadening the range of physical activities available on the platform.
days to go:
Expired
investment:
£1,440,500
